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Objectives: The incidence of cystic ﬁbrosis (CF) in Estonia is 1 in 7700 live
births. The aim of this study was to analyze the demographic and clinical data of
CF patients in Estonia on the census date (01/12/2010) and compare them to earlier
data of 1993 and 2003.
Methods: There are 45 (26 males and 19 females) alive CF patients in Estonia.
Clinical data of 39 patients, who have been in regular follow up in 2009/2010 at
Children’s Clinic of TUH (21), Tallinn Children’s Hospital (17) and North Estonia
Medical Centre (1), were reviewed.
Results: The mean age of our CF patients has increased from 8 y 2mo (1993) to
15 y 5mo (2010). In 1993 there was no patient >18years old vs. 29% (9/31) in 2003
and 38% (17/45) in 2010. The median age at diagnosis of CF in Estonian patients
(1 year 6 months) is still higher than in the EU countries. The chronic P. aeruginosa
colonisation was found in 18/39 and S. aureus in 14/39 patients. Majority of patients
(84%) had good lung function according to FEV1 predicted >70%. The mean value
for FEV1 was 91.1 % (95%CI 75.6–106.5) and for FVC 89.4 % (95%CI 60.5–
118.5). Chronic liver disease was detected in 12/39 and diabetes only in 2 patients.
One 12 old year girl with liver cirrhosis had liver transplantation. Comparing
mortality rates throughout the following periods, a signiﬁcant decline has been
detected: from 12.2% (1983–1987) to 0.66% (2003–2010).
Conclusions: In Estonia slight but steady improvement in the survival of patients
and their quality of life has been observed due to consistent changes in their follow
up, centralized healthcare system and treatment options.
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The aim was to analyze the clinical-laboratorial characteristics of CF at diagnosis
in RJ where incidence is estimated as 1:6902. It is a descriptive and sectional study
of patients followed from Jan/08 to Sept/09. The diagnosis was made through
the manifestation of the disease plus the sweat test. PI was deﬁned by enzyme
replacement; malnutrition weight/age, weight/stature/age, gender in 2 yo, and
BMI for >2 yo; morbidity; manifestations and hospitalization. In 105 patients,
55% were female, 58% white and 97% RJ residents. We veriﬁed a delay of
11 months between median ages at diagnosis and the onset of symptoms: 14mo and
1.7mo. CF was manifested by meconial ileum (9.6%); edema and anemia (9.6%);
dehydration (29.8%); poor absorption (85%); PI (89.5%); malnutrition in patients
aged 2 (54.1%) and >2 (44.2%); coughing (87.6%), dyspnea (75.2%), thoracic
deformity (30.5%), digital hippocratism (28.6%), P. aeruginosa (45.6%), S. au-
reus (34.4%), B. cepacia complex (5.6%). Patients who needed hospital treat-
ment (46.7%), 66% with previous hospitalizations, 61% <1 yo. Identiﬁed mutations
in 2 alleles in 38.6%: DF508/DF508 (15/70), DF508/other (7), other/other (1); and
in 1 allele 40%: DF508/Unknown(U) (18), other/U (10), and U/U (15/70).
We highlight the following possible risk factors associated with morbidity: difﬁculty,
delay and confusing it with comorbidities associated with prevalent diseases −
malnutrition, diarrhea, dehydration, pneumonia, in addition to severe mutations.
Early diagnosis and adequate interventions are necessary to reduce morbimortality
which contrasts with the challenge posed on the genotypic determination of the
studied population for therapeutical ends.
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In 2007 an EPR system (EMIS®) was introduced at the Leeds Adult CF unit to
improve service efﬁciency and patient care. Prior to EPR it had become increasingly
difﬁcult to deliver timely annual assessments (AA) and GP correspondence due to
increasing patient numbers, a high DNA rate and limited stafﬁng resources. The
introduction of EPR enabled continuous patient monitoring and assessment. We
report the impact of EPR on delivery of AA and clinical correspondence.
Data was collected pre and post introduction of EPR. Pre EPR patients attended
for a full day’s review and the AA details and results handwritten and summary
dictated and typed. EPR an online diary alerts users when individual parts of
AA are required. Results are entered electronically and acted on according to
level of urgency. Consultation and discharge summaries post EPR are generated
automatically in real time.
Pre EPR (2005) only 40% of total population attended for full AA. Median (range)
number of days for summary to be dictated and typed was 48 (26−78) days.
Post EPR the percentage of patients who had AA bloods, OGTT and U/S increased
from 63%, 64% and 45% in 2005 to 92%, 89% and 86% respectively in 2010. Total
time to sending a discharge summary to GP was reduced from a median (range) of
19.5 days (4−40) pre EPR to 1 (0−2) days with EPR. Clinic letters now generated
at the time of consultation alleviating the need for dictation.
Despite increasing patient numbers and limited stafﬁng resources the use of EPR
technology has enabled us to deliver a more efﬁcient and effective service. EPR is
an essential patient management tool and further investment in new technologies is
ongoing.
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Objectives: to describe the new beginning of the Brazilian Cystic Fibrosis Registry
(REBRAFC).
Methods: Initial conversations to restart the Brazilian CF registry occurred in early
2007 and the proposition of a Web based platform was done. The new Brazilian
Registry was fully supported by the Brazilian Group of Studies of Cystic Fibrosis
(GBEFC). The development of the Web based platform was done by the Laboratory
of Integrated Systems (LSI), from the Politecnica School of Engineering, University
of Sao Paulo. The modeling and project of the system used methods based on
Uniﬁed Modeling Language (UML). Free and open software were adopted for
programming, and the security of the system was planned in several layers using
interceptions provided by the Struts2 framework. The main contents of the registry
were Demographics, Diagnosis data and Clinical data. This last item would be
inserted annually, including number of consultations, nutritional and functional
data, current treatments, microbiology data and Schwachman-Kulczycki score.
Identiﬁcation of patients is protected. After initial testing of the platform, all known
Centers and health professionals involved in CF care were invited to join the
Registry. A formal contract was celebrated among the GBEFC and each Center
to guarantee the conﬁdentiality of the data. The start of data insertion took place in
March 2010, but was very modest until the occurrence of the Brazilian CF Congress
in September 2010. Approximately 1,400 patients were included until January 2011
(near one-third of all Brazilian CF patients).
Conclusions: The new Brazilian CF Registry is fully operational but strategies to
improve adhesion are needed.
